Trametinib
Orphan DrugFDA Approved
Contents
Description
Trametinib is a kinase inhibitor indicated, in combination with dabrafenib, for the treatment of anaplastic thyroid cancer with BRAF V600E mutation. It inhibits MEK1 and MEK2 kinases, which are involved in cell signaling and growth.
Indications & Therapeutic Use
Anaplastic thyroid cancer with BRAF V600E mutation
Linked Diseases:
Global Availability (2 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — |
Buy / Source Trametinib — GNH India
28 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Mekinist
0.5mgtabletSwitzerland
Meqsel 2mg
2mgtabletIndia
Spexotras
EU
Meqsel 0.5mg
0.5mgtabletIndia
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Trametinib
| Generic Name | Trametinib |
| Brands | 1 brand available |
| Active Ingredient | Trametinib dimethyl sulfoxide |
| Drug Class | Anaplastic thyroid cancer with BRAF V600E mutation |
| Manufacturer | Novartis |
| Dosage Forms | Tablet |
| Medical Code | L01EE07 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Reg. Status | FDA Approved |
| Countries | 2 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations3 Validated Nodes